PET/CT and SPECT/CT: Theory, Practice and Clinical Experience
September 6 -  8

 PET/CT and SPECT/CT: Theory, Practice and Clinical Experience

 

                                   DAY 1 - Monday, September 6, 2010

 

7:30 - 8:00 am Introduction (PET/CT and SPECT/CT):  (George Sfakianakis MD)                                  

     Anatomy and Function – Molecular Imaging: Biologic Recognition - Small Size Tracers: DeOxyGlucose

    Positron Emitters – PET Imaging-Need PET/CT (Anatomic Localization and Attenuation Correction)

     Fusion PET/CT Advantages/Disadvantages – The emergence of SPECT/CT – Reimbursement issues.

 

8:00 - 8:45 am Instrumentation (PET/CT and SPECT/CT): (Mike Georgiou PhD)                                  

     Coincidence – Time of Flight – Attenuation Correction and Accurate Localization

    (Role of Non-diagnostic CT) – Fusion of PET/SPECT and CT – Motion Correction –

     Quantification - SUVs - Contrast administration - Low dose CT 

 

8:45 - 9:30 am  Current Oncologic Applications:  (Sundeep Nayak MD)                                                

General Overview of Current Clinical Applications of FDG-PET/CT and SPECT/CT 

Initial and subsequent treatment strategies; Evaluation for post-therapeutic effects, recurrence and

planning for radiation therapy; NOPR and non-covered indications.

 

9:30 - 10:15 am  How we read a PET-SPECT/CT: (G.N.Sfakianakis MD)                                                  

     Rotating 3D total body PET images: All the information is there. Learn to appreciate it.

    Tomographic PET and fused with CT images (localization of Normal and Abnormal findings)

    Quantification (SUVs) – Comparison of Follow Up studies- Non-attenuation Corrected Images

    (their usefulness). Reporting (History/Method/Findings/Significance/Suggestions/Impression)

 

10:15 - 10:30 am Break 

 

10:30 - 11:15 am  Clinical Experience with SPECT/CT: (Jerry Froelich MD)                                             

          Parathyroid adenomas (Sestamibi SPECT/CT). Benign Bone diseases (Bone SPECT/CT)

          Infection Localization (Gallium/Labeled WBC SPECT/CT)

          Tumor Imaging SPECT/CT (Octreoscan/Prostascint/Skeletal Metastasis etc)

 

11:15 - 12:00 pm  Bones: Primary and Metastatic Tumors Evaluation: (Jerry Froelich MD)                   

      TcMDP (HDP) Planar v/s SPECT/CT v/s NaF-PET/CT. Bone scan v/s FDG-PET/CT.

      Evaluation of Primary and Metastatic bone tumors. Individual merits and disadvantages

 

                                                                

12:00 - 12:45 pm  Melanoma/Sarcomas: (Jerry Froelich MD)                                                                         

Initial Diagnosis/Localization and Extent of the disease

Follow up Effect of Therapy (the two cycles principle?)/evaluate for Recurrence

                                                    

 

12:45 - 1:00 pm Questions and Answers on the days topics    (All this day’s Faculty)                         

 

 

                                    DAY 2 - Tuesday, September 7, 2010

 

 

7:30 - 8:15 am  Normal FDG Study and Variations. The Total Body concept: (G.N.Sfakianakis)           

      The FDG/PET total body study: Normal and Variations. What we miss if we do not examine

      the total body. Tumors/Indications that need it (Specific tumors/Distal Metastases/Unknown Primary).

      Discovery of a second tumor. Inflammatory/Infectious Accumulations

 

8:15 - 9:00 am Artifacts and Nodes: Recognize and Respond:  (Sundeep Nayak MD)                                                           

       Prevention, recognition and response to commonly encountered artifacts.

      Systematic evidence-based approach to nodal analysis above and below the diaphragm 

 

9:00 - 9:45 am PET/CT in the diagnosis and management of Brain, Head/Neck and Thyroid Cancers: (George Segall MD)

PET for Brain tumors.  FDG-PET/CT for Initial Diagnosis/Localization and Extent of Head and Neck Cancer. Follow up studies for Effect of Therapy, Evaluation for Recurrence. Contrast administration

Contribution of FDG-PET/CT in the diagnosis and therapy of recurrence or residual thyroid cancer

(Iodine avid and non-avid)

                                    

9:45 - 10:30 am Lymphoma: (Sundeep Nayak MD)                                                                                      

Initial and subsequent treatment strategies for Lymphoma sub types;

Unified approach to Lymphoma staging;

Application of the International Harmonization Project for response criteria.

                                                        

 10:30 - 10:45 am Break                                                             

 

10:45 - 11:30 am New PET/CT protocols for the optimized management of Patients with cancer:  (George Segall MD)

     Non-diagnostic CT (radiation issues) and Contrast administration

     New developments and proposals for a better practice

 

11:30 - 12:15 pm Emerging/Research/New Molecular Imaging Agents for PET and SPECT/CT:  (George Segall MD)

     Thorough review of the recently developed (and currently under clinical investigation/trials)

     new PET (SPECT) Molecular Imaging agents, including F-DOPA, Amino Acids etc.

     Current Research for new Molecular Imaging agents. 

 

12:15 - 1:00 pm PET/CT and SPECT/CT for Non-Cancer evaluations: (George Sfakianakis MD)       

        Myocardial Perfusion and Viability. Infection/Inflammation localization.

        Brain Studies (Alzheimer’s, Infarcts, Parkinson’s etc).

 

1:00 - 1:15 pm Questions and Answers on the days topics     (All this day’s Faculty)                             

 

                               

                                         DAY 3 - Wednesday, September 8, 2010

 

7:30 - 8:20 am Chest Tumors with FDG PET/CT:  (Homer Macapinlac MD)                                           

        a. Lungs/Mediastinum (Staging of NSCLC - The new staging system implementation (IASLC).

          The CT and PET/CT staging criteria and minimally invasive nodal staging procedures (EBUS or EUS)

        b. Breasts Cancer

Initial Diagnosis/Localization and Extent of the disease

Follow up Effect of Therapy/Evaluation for Recurrence

 

8:20 - 9:10 am Abdominal Tumors with FDG PET/CT: (Homer Macapinlac MD)                                     

        a. Esophageal cancer - pre therapy, monitoring response, and restaging for recurrence 

        b. Other Abdominal Cancers (Pancreatic/Liver/Small Bowel/Kidneys/Adrenal)

            Primary and Metastatic cancers

Initial Diagnosis/Localization and Extent of the disease. Follow up and Effect of Therapy/Evaluation for Recurrence

                                                           

9:10 - 9:55 am Pelvic Tumors with FDG PET/CT:  (Homer Macapinlac MD)                                            

      a. Rectosigmoid Cancer

Initial Diagnosis/Localization and Extent of the disease

Follow up Effect of Therapy/ Evaluation for Recurrence

b. Gynecological/Testicular/Renal/Bladder Cancers

  Initial Diagnosis/Localization and Extent of the disease

  Follow up Effect of Therapy/ Evaluation for Recurrence

 

 9:55 - 10:15 am Break                                                                    

10:15 - 11:00 am PET and SPECT/CT in Pediatric Age (Barry Shulkin MD)                                                 

      General Issues for PET(/CT) and SPECT/CT in Children for Tumor and Non-Tumor imaging,

       Imaging with other than FDG PET agents and The Low-Dose Whole-Body Protocols

 

11:00 - 11:45 am PET and SPECT/CT in Pediatric Tumor Imaging (Barry Shulkin MD)                            

        Imaging of pediatric tumors with FDG/PET and comparison with other imaging agents

        Imaging tumors with other than FDG PET agents and with SPECT agents

 

11:45 - 12:30 pm SPECT/CT The MD Anderson Experience: (Homer Macapinlac MD)                              

Malignant Skeletal Tumors SPECT/CT

          SPECT/CT Tumor Imaging (Octreoscan/Prostascint/MIBG and other) 

12:30 - 12:45 pm Questions and Answers on all topics     (All this day’s Faculty)